Literature DB >> 12176989

Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.

Adrian S Ray1, Aravind Basavapathruni, Karen S Anderson.   

Abstract

Abacavir has been shown to select for multiple resistant mutations in the human immunodeficiency type 1 (HIV-1) pol gene. In an attempt to understand the molecular mechanism of resistance in response to abacavir, and nucleoside analogs in general, a set of reverse transcriptase mutants were studied to evaluate their kinetics of nucleotide incorporation and removal. It was found that, similar to the multidrug-resistant mutant reverse transcriptase (RT)(Q151M), the mutations L74V, M184V, and a triple mutant containing L74V/Y115F/M184V all caused increased selectivity for dGTP over the active metabolite of abacavir (carbovir triphosphate). However, the magnitude of resistance observed in cell culture to abacavir in previous studies was less than that observed to other compounds. Our mechanistic studies suggest that this may be due to carbovir triphosphate decreasing the overall effect on its efficiency of incorporation by forming strong hydrophobic interactions in the RT active site. Unlike RT(AZTR), no increase in the rate of ATP- or PP(i)-mediated chain terminator removal relative to RT(WT) could be detected for any of the mutants. However, marked decreases in the steady-state rate may serve as a mechanism for increased removal of a chain-terminating carbovir monophosphate by increasing the time spent at the primer terminus for some of the mutants studied. The triple mutant showed no advantage in selectivity over RT(M184V) and was severely impaired in its ability to remove a chain terminator, giving no kinetic basis for its increased resistance in a cellular system. Biochemical properties including percentage of active sites, fidelity, and processivity may suggest that the triple mutant's increased resistance to abacavir in cell culture is perhaps due to a fitness advantage, although further cellular studies are needed to verify this hypothesis. These data serve to further the understanding of how mutations in RT confer resistance to nucleoside analogs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176989     DOI: 10.1074/jbc.M205303200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.

Authors:  Marc Wirden; Bénédicte Roquebert; Anne Derache; Anne Simon; Claudine Duvivier; Jade Ghosn; Stephanie Dominguez; Véronique Boutonnet; Zaina Ait-Arkoub; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.

Authors:  Michael E Abram; Andrea L Ferris; Kalyan Das; Octavio Quinoñes; Wei Shao; Steven Tuske; W Gregory Alvord; Eddy Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

5.  A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.

Authors:  Antonio J Acosta-Hoyos; Suzanne E Matsuura; Peter R Meyer; Walter A Scott
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

6.  Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.

Authors:  Yagmur Muftuoglu; Christal D Sohl; Andrea C Mislak; Hiroaki Mitsuya; Stefan G Sarafianos; Karen S Anderson
Journal:  Antiviral Res       Date:  2014-03-12       Impact factor: 5.970

7.  Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.

Authors:  Renxiang Chen; Masaru Yokoyama; Hironori Sato; Cavan Reilly; Louis M Mansky
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.

Authors:  Karidia Diallo; Bruno Marchand; Xin Wei; Luciano Cellai; Matthias Götte; Mark A Wainberg
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Mutations in human DNA polymerase γ confer unique mechanisms of catalytic deficiency that mirror the disease severity in mitochondrial disorder patients.

Authors:  Christal D Sohl; Rajesh Kasiviswanathan; William C Copeland; Karen S Anderson
Journal:  Hum Mol Genet       Date:  2012-12-03       Impact factor: 6.150

Review 10.  HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Authors:  Kalyan Das; Eddy Arnold
Journal:  Curr Opin Virol       Date:  2013-04-19       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.